Hikma Has A First With Labetalol Launch In US
Also Introduces Hydralazine And Estradiol Valerate As Part Of Latest Injectables Push
Hikma says it is breaking new ground in the US with a ready-to-use presentation of labetalol. Meanwhile, the company has also added hydralazine to its list of recent injectables launches.
You may also be interested in...
Trio Of Hikma Launches Includes New Icosapent Strength
Hikma has launched three new generics in quick succession, including a new strength of its icosapent ethyl capsules that rival Vascepa, as well as unique presentations of its cefazolin and labetalol injectables.
Hikma Launches Nasal Naloxone Spray In US
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.
Hikma Has A Trio Of US Launches
Hikma has added three products – a generic version of Banzel tablets and injectables ganciclovir and doxycycline – to its US portfolio.